Via practica S4/2007

MANAGEMENT OF ATHEROGENIC DYSLIPIDAEMIA IN THE METABOLIC SYNDROME

The main modifiable risk factor for atherosclerosis is the atherogenic dyslipidaemia (the combination of elevated serum triglyceride levels, low serum HDL-C levels, and a preponderance of small dense LDL-C particles), particulary for patients with the metabolic syndrome. It has been suggested that the clinical importance of the atherogenic dyslipidaemia probably exceeds that of LDL-cholesterol, because many more patients with coronary artery disease are found to have this trait compared to those with hypercholesterolemia. The pathogenesis of dyslipidemia in the metabolic syndrome will be reviewed and the roles of therapeutic lifestyle modification and drug therapies in the traetment of dyslipidemia will be discussed (tablet 5, figure 1; 46).

Keywords: metabolic syndrome, atherogenic dyslipidaemia, non-pharmacological therapy, statins, fibrates, combined therapy.